amlodipine besylate Articles
Japan briefs: Takeda files for Azilva comb; Sandoz seeks filgrastim biosimilar approval
29 April 2013
XOMA's perindopril and amlodipine FDC meets primary endpoint in Ph III blood pressure trial
23 November 2012
The “new” Pfizer sees 4th qtr s2009 sales and profit rocket, but 2010 guidance disappoints
4 February 2010
Philippines seeks more voluntary drug price reductions
19 January 2010
Ranbaxy to launch Daiichi Sankyo’s olmesartan in six African markets
23 December 2009
Daiichi Sankyo's Azor improves 24-hour ABP
12 May 2009
Japan stock market week to April 6, 2009
7 April 2009
French pharmacy sales up only 1.8% in 2008
6 April 2009
PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app
12 January 2009
UPDATE: Pfizer quits cholesterol sector seeking profit
6 October 2008
Pfizer quits cholesterol sector seeking profit
6 October 2008
Flat pharma sales reported in Japan
29 September 2008
Japan stock market week to Sept 22, 2008
29 September 2008
463 generics added to Japan's NHI list
14 July 2008
Mylan sued by Daiichi Sankyo over Azor patent
9 June 2008
Foreign generics firms on offensive in Japan
2 June 2008
Pfizer moves to keep market share in Japan
24 March 2008
Pfizer sees 4th-qtr 2007 profits decline, but still beats forecasts; revenue rises 4%
28 January 2008
Caraco gets FDA OK for generic Norvasc
10 December 2007
Raft of pending patent expiries threaten cardiovascular blockbusters
10 December 2007
France's new proposals to widen Rx switching
3 December 2007
US Rx drug market in relative decline
12 November 2007
Japan stock market week to September 24, 2007
1 October 2007
Daiichi Sankyo and Forest sign US promotion deal
3 September 2007
Dr Reddy's 1st-qtr 2008 profits up 30%
30 July 2007
Pfizer
23 July 2007
Final FDA approval for Ranbaxy's amlodipine
16 July 2007
Nuvelo begins R&D collaboration with Kirin Brewery
25 June 2007
Japan stock market week to May 28, 2007
4 June 2007
Exforge cuts mean bp 20mmHg in Ph III trial
28 May 2007
Novartis' 1st-qtr 2007 profit up 11% to $2.17B on strong sales of cancer drugs and Diovan
30 April 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
FDA disallows generic amlodipine other than Mylan's
23 April 2007
Mylan raises EPS guidance on strong generic sales
16 April 2007
Stock Commentary - New York week to April 2
9 April 2007
Pfizer to launch generic version of Norvasc
2 April 2007
Stock Commentary - New York week to March 26
2 April 2007
Appeals court reverses decision on Pfizer's Norvasc
2 April 2007
Stock Commentary - New York week to March 5, 2007
12 March 2007
Pfizer wins Norvasc patent challenge from Mylan
5 March 2007
Opportunities for Japanese generics
5 March 2007
US Court rules in Pfizer's favor over Norvasc
12 February 2007
Novartis' Exforge cleared by EU regulator
29 January 2007
Novartis' Exforge approved by FDA
8 January 2007
Lipitor/Norvasc combo cuts heart attack risk 53%
11 December 2006
Japan stock market week to Dec 4, 2006
11 December 2006
Pfizer's massive R&D spend to continue as firm pledges unprecedented innovation drive
11 December 2006
Daiichi Sankyo files NDA for combo CV drug
4 December 2006
Pfizer to lose 20% of US sales force as it cuts costs
4 December 2006
Fake hypertension drug found in Taiwan
27 November 2006
Novartis sees 16% sales jump in first three qtrs of 2006 beating consensus estimates
30 October 2006
Pfizer's Caduet reduces 10-yr CV risk by 54%
23 October 2006
Amlodipine lowers diabetes risk in hypertensives
18 September 2006
Pfizer defends Norvasc patent from Synthon
11 September 2006
Japan stock market week to Sept 4, 2006
11 September 2006
Jury says Pfizer does not infringe Synthon patent
28 August 2006
Teva gets tentative FDA OK for generic Lotrel
17 July 2006
BI's Micardis lowers BP more than other ARBs
26 June 2006
Novartis reports strong Ph III results for SPP100
30 January 2006
US court upholds Pfizer's Norvasc patent
30 January 2006
New Zealand: full funding for cardiac drugs
19 December 2005
Pfizer Germany sees 2006 recovery
12 September 2005
USA
22 August 2005
New data shows CV benefits for Novartis' Diovan
4 July 2005
Novartis' Diovan cuts diabetes risk
30 May 2005
World retail Rx sales up 6% in 12 mnths to Jan
4 April 2005
Norvasc's therapeutic benefit confirmed
14 March 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
